Key result
LAA ligation using the LARIAT suturing device resulted in a 3.6% annual stroke rate, representing a 32% reduction compared to the expected risk based on the CHADS2 score.
Why the study?
Does percutaneous left atrial appendage ligation using the LARIAT suturing device prevent systemic embolic events and strokes in patients with atrial fibrillation?
Observational (n=21)
No
Does percutaneous left atrial appendage ligation using the LARIAT suturing device prevent systemic embolic events and strokes in patients with atrial fibrillation?
LAA ligation using the LARIAT suturing device is clinically feasible in carefully selected patients with atrial fibrillation, though long-term efficacy for stroke reduction requires further study.
Should not yet change practice for LAA ligation in AF; leaves open efficacy confirmation in randomized trials.
BACKGROUND: The left atrial appendage (LAA) is the source of considerable thromboemboli responsible for embolic strokes in patients with atrial fibrillation (AF). The LARIAT™ suturing device has been used to ligate the LAA and negate the use of systemic anticoagulation. However, its efficacy and stroke outcome is still unknown. METHODS: We retrospectively evaluated the clinical status and risk of occurrence of systemic emobolic events, strokes, transient ischemic attacks, and procedure related complications in patients after LAA ligation using the LARIAT™ device. CONCLUSION: LAA ligation using the LARIAT™ suturing device is clinically feasible in carefully selected patients. This study has the longest follow up period to date, however further studies are required to determine the efficacy of stroke reduction and long-term clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Khodjaev et al. (2014) conducted an observational in Atrial fibrillation (n=21). LAA ligation using LARIAT suturing device vs. Expected risk based on CHADS2 score was evaluated on Occurrence of systemic thromboembolic events or TIA. LAA ligation using the LARIAT suturing device resulted in a 3.6% annual stroke rate, representing a 32% reduction compared to the expected risk based on the CHADS2 score.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: